Felipe Ades

LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)

Sherene Loi, Giuseppe Curigliano, Roberto Salgado et al. · Annals of Oncology · 2023 · 99 citations · Full text

Breast Oncology, Oncology, Medicine +9

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states

Felipe Ades, Christelle Senterre, Evandro de Azambuja et al. · Annals of Oncology · 2013 · 72 citations · Full text

Cancer Epidemiology, Health Policy, Health Economics +7

1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial

Benjamin Solomon, Alexander Drilon, Lyudmila Bazhenova et al. · Annals of Oncology · 2023 · 51 citations · Full text

Solid Tumors, Medicine, Radiopharmaceutical Therapy +7

Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8

Guy Jérusalem, Aleix Prat, Roberto Salgado et al. · The Breast · 2023 · 38 citations · Full text

Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months

Begoña de las Heras, Kamal S. Saini, Frances Boyle et al. · Oncology and Therapy · 2020 · 31 citations · Full text